Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Breast Cancer Res
    April 2024
  1. ZHANG W, Song X, Jin Z, Zhang Y, et al
    U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
    Breast Cancer Res. 2024;26:60.
    >> Share

  2. KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
    Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival.
    Breast Cancer Res. 2024;26:61.
    >> Share

  3. WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
    Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Breast Cancer Res. 2024;26:59.
    >> Share

  4. BASHARI MH, Fan F, Vallet S, Sattler M, et al
    Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
    Breast Cancer Res. 2024;26:58.
    >> Share

    March 2024
  5. OLIPHANT MUJ, Akshinthala D, Muthuswamy SK
    Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.
    Breast Cancer Res. 2024;26:56.
    >> Share

  6. CHI F, Griffiths JI, Nath A, Bild AH, et al
    Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Breast Cancer Res. 2024;26:54.
    >> Share

  7. SAFAEI S, Fadaee M, Farzam OR, Yari A, et al
    Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.
    Breast Cancer Res. 2024;26:57.
    >> Share

  8. WALLACE G, Kundalia R, Vallebuona E, Cao B, et al
    Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
    Breast Cancer Res. 2024;26:55.
    >> Share

  9. MULLOOLY M, Fan S, Pfeiffer RM, Bowles EA, et al
    Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease.
    Breast Cancer Res. 2024;26:52.
    >> Share

  10. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:53.
    >> Share

  11. HAMILTON AM, Walens A, Van Alsten SC, Olsson LT, et al
    BIRC5 expression by race, age and clinical factors in breast cancer patients.
    Breast Cancer Res. 2024;26:50.
    >> Share

  12. MCCLELLAN JC, Li JL, Gao G, Huo D, et al
    Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status.
    Breast Cancer Res. 2024;26:51.
    >> Share

  13. LEE J, Lee G, Park HS, Jeong BK, et al
    Factors associated with engraftment success of patient-derived xenografts of breast cancer.
    Breast Cancer Res. 2024;26:49.
    >> Share

  14. HU R, Cao Y, Wang Y, Zhao T, et al
    TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via beta1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Breast Cancer Res. 2024;26:48.
    >> Share

  15. GONZALEZ-FERNANDEZ L, Romero-Morales C, Martinez-Pascual B, Rio-Gonzalez A, et al
    Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study.
    Breast Cancer Res. 2024;26:47.
    >> Share

  16. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
    Breast Cancer Res. 2024;26:46.
    >> Share

  17. PEREIRA A, Garmendia ML, Leiva V, Corvalan C, et al
    Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study.
    Breast Cancer Res. 2024;26:45.
    >> Share

  18. JACOBS LM, Helder LS, Albers KI, Kranendonk J, et al
    The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study.
    Breast Cancer Res. 2024;26:42.
    >> Share

  19. CONNER SJ, Guarin JR, Le TT, Fatherree JP, et al
    Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.
    Breast Cancer Res. 2024;26:43.
    >> Share

  20. BAEZ-NAVARRO X, van den Ende NS, Nguyen AH, Sinke R, et al
    HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Breast Cancer Res. 2024;26:41.
    >> Share

  21. LI J, Liang Y, Zhou S, Chen J, et al
    UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
    Breast Cancer Res. 2024;26:44.
    >> Share

  22. ZHAO L, Xing Y, Liu C, Ma S, et al
    Detection of HER2 expression using (99m)Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
    Breast Cancer Res. 2024;26:40.
    >> Share

  23. CASTRESANA-AGUIRRE M, Johansson A, Matikas A, Foukakis T, et al
    Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Breast Cancer Res. 2024;26:38.
    >> Share

  24. HAN Y, Otegbeye EE, Stoll C, Hardi A, et al
    How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis.
    Breast Cancer Res. 2024;26:39.
    >> Share

  25. JIANG X, Wang Y, Guo L, Wang Y, et al
    The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
    Breast Cancer Res. 2024;26:37.
    >> Share

  26. RODON J, Demanse D, Rugo HS, Burris HA, et al
    A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
    Breast Cancer Res. 2024;26:36.
    >> Share

  27. SMOOTS SG, Schreiber AR, Jackson MM, Bagby SM, et al
    Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Breast Cancer Res. 2024;26:35.
    >> Share

    February 2024
  28. SONG T, Zhang H, Zhao Q, Hu Z, et al
    Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
    Breast Cancer Res. 2024;26:33.
    >> Share

  29. EDWARDS CM, Kane JF, Smith JA, Grant DM, et al
    PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
    Breast Cancer Res. 2024;26:34.
    >> Share

  30. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
    Breast Cancer Res. 2024;26:32.
    >> Share

  31. JUNG M, Song SG, Cho SI, Shin S, et al
    Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
    Breast Cancer Res. 2024;26:31.
    >> Share

  32. HEESCH A, Florea A, Maurer J, Habib P, et al
    The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [(177)Lu]Lu-PSMA-I&T for triple-negative breast cancer.
    Breast Cancer Res. 2024;26:30.
    >> Share

  33. DEROUANE F, Desgres M, Moroni C, Ambroise J, et al
    Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.
    Breast Cancer Res. 2024;26:29.
    >> Share

  34. SCHEFFGES C, Devy J, Giustiniani J, Francois S, et al
    Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
    Breast Cancer Res. 2024;26:28.
    >> Share

  35. LI JK, Jin ZY, Xu YJ, Fu NQ, et al
    Contrast-enhanced ultrasound to predict malignant upgrading of atypical ductal hyperplasia.
    Breast Cancer Res. 2024;26:27.
    >> Share

  36. WANG M, Du S, Gao S, Zhao R, et al
    MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Breast Cancer Res. 2024;26:26.
    >> Share

  37. SANTERAMO R, Damiani C, Wei J, Montana G, et al
    Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case-control study.
    Breast Cancer Res. 2024;26:25.
    >> Share

  38. RONNLUND C, Sifakis EG, Schagerholm C, Yang Q, et al
    Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:24.
    >> Share

  39. LUNDBERG P, Abrahamsson A, Kihlberg J, Tellman J, et al
    Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women.
    Breast Cancer Res. 2024;26:22.
    >> Share

  40. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:23.
    >> Share

  41. LEE J, Nishikawa RM
    Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover.
    Breast Cancer Res. 2024;26:21.
    >> Share

    January 2024
  42. LYNCE F, Stevens LE, Li Z, Brock JE, et al
    TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
    Breast Cancer Res. 2024;26:20.
    >> Share

  43. NIE J, Dang S, Zhu R, Lu T, et al
    ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
    Breast Cancer Res. 2024;26:19.
    >> Share

  44. HAN X, Guo Y, Ye H, Chen Z, et al
    Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Breast Cancer Res. 2024;26:18.
    >> Share

  45. SHARMA A, Weitz P, Wang Y, Liu B, et al
    Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer.
    Breast Cancer Res. 2024;26:17.
    >> Share

  46. SUN X, Reiner AS, Tran AP, Watt GP, et al
    A genome-wide association study of contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology Study.
    Breast Cancer Res. 2024;26:16.
    >> Share

  47. KANG E, Jung JJ, Lim C, Kim HK, et al
    Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.
    Breast Cancer Res. 2024;26:14.
    >> Share

  48. NABILA S, Choi JY, Abe SK, Islam MR, et al
    Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea.
    Breast Cancer Res. 2024;26:15.
    >> Share

  49. FISHER TB, Saini G, Rekha TS, Krishnamurthy J, et al
    Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:12.
    >> Share

  50. PARK J, Chang ES, Kim JY, Chelakkot C, et al
    c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2024;26:13.
    >> Share

  51. BAGGER MM, Sjolund J, Kim J, Kohler KT, et al
    Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer.
    Breast Cancer Res. 2024;26:11.
    >> Share

  52. PENG ZM, Han XJ, Wang T, Li JJ, et al
    PFKP deubiquitination and stabilization by USP5 activate aerobic glycolysis to promote triple-negative breast cancer progression.
    Breast Cancer Res. 2024;26:10.
    >> Share

  53. DING N, Pang J, Liu X, He X, et al
    Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
    Breast Cancer Res. 2024;26:9.
    >> Share

  54. PADAMSEE TJ, Bijou C, Swinehart-Hord P, Hils M, et al
    Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey.
    Breast Cancer Res. 2024;26:8.
    >> Share

  55. DELL'AQUILA K, Vadlamani A, Maldjian T, Fineberg S, et al
    Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.
    Breast Cancer Res. 2024;26:7.
    >> Share

  56. BLOCK I, Mateu-Regue A, Do TTN, Miceikaite I, et al
    Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variant.
    Breast Cancer Res. 2024;26:6.
    >> Share

  57. HACHEY SJ, Hatch CJ, Gaebler D, Mocherla A, et al
    Targeting tumor-stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model.
    Breast Cancer Res. 2024;26:5.
    >> Share

  58. LOPEZ-VELAZCO JI, Manzano S, Otano M, Elorriaga K, et al
    A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2024;26:3.
    >> Share

  59. BRAUNE EB, Geist F, Tang X, Kalari K, et al
    Identification of a Notch transcriptomic signature for breast cancer.
    Breast Cancer Res. 2024;26:4.
    >> Share

  60. TAO J, Xue C, Cao M, Ye J, et al
    Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway.
    Breast Cancer Res. 2024;26:1.
    >> Share

  61. ZIRPOLI GR, Pfeiffer RM, Bertrand KA, Huo D, et al
    Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women.
    Breast Cancer Res. 2024;26:2.
    >> Share

    December 2023
  62. GUAN Y, Shen J, Lu J, Fuemmeler BF, et al
    Association between allostatic load and breast cancer risk: a cohort study.
    Breast Cancer Res. 2023;25:155.
    >> Share

  63. CHENG HF, Tsai YF, Liu CY, Hsu CY, et al
    Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Breast Cancer Res. 2023;25:152.
    >> Share

  64. DAYAN D, Lukac S, Rack B, Ebner F, et al
    Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
    Breast Cancer Res. 2023;25:153.
    >> Share

  65. SEO J, Koh J, Lee DW, Kim J, et al
    HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
    Breast Cancer Res. 2023;25:154.
    >> Share

  66. OLIVOS N, Banta JE, Spencer-Hwang R, Ansong D, et al
    Mosquito control exposures and breast cancer risk: analysis of 1071 cases and 2096 controls from the Ghana Breast Health Study.
    Breast Cancer Res. 2023;25:150.
    >> Share

  67. HU P, Zhou P, Sun T, Liu D, et al
    Therapeutic protein PAK restrains the progression of triple negative breast cancer through degrading SREBP-1 mRNA.
    Breast Cancer Res. 2023;25:151.
    >> Share

  68. HUNG SK, Yang HJ, Lee MS, Liu DW, et al
    Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study.
    Breast Cancer Res. 2023;25:149.
    >> Share

    November 2023
  69. TAN Z, Deme P, Boyapati K, Claes BSR, et al
    Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:148.
    >> Share

  70. ATAKPA EC, Buist DSM, Aiello Bowles EJ, Cuzick J, et al
    Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study.
    Breast Cancer Res. 2023;25:147.
    >> Share

  71. GOKER M, Denys H, Hendrix A, De Wever O, et al
    Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer.
    Breast Cancer Res. 2023;25:146.
    >> Share

  72. VERSCHOOR N, Smid M, Jager A, Sleijfer S, et al
    Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
    Breast Cancer Res. 2023;25:145.
    >> Share

  73. SHARMA D, Hager CG, Shang L, Tran L, et al
    The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling.
    Breast Cancer Res. 2023;25:144.
    >> Share

  74. FRANCO-VALLS H, Tusquets-Uxo E, Sala L, Val M, et al
    Formation of an invasion-permissive matrix requires TGFbeta/SNAIL1-regulated alternative splicing of fibronectin.
    Breast Cancer Res. 2023;25:143.
    >> Share

  75. ASWOLINSKIY W, Munari E, Horlings HM, Mulder L, et al
    PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
    Breast Cancer Res. 2023;25:142.
    >> Share

  76. CAMPONE M, Bidard FC, Neven P, Wang L, et al
    AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.
    Breast Cancer Res. 2023;25:141.
    >> Share

  77. BRACKENBURY WJ, Palmieri C
    Blocking channels to metastasis: targeting sodium transport in breast cancer.
    Breast Cancer Res. 2023;25:140.
    >> Share

  78. NIELSEN K, Sode M, Jensen MB, Berg T, et al
    High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients.
    Breast Cancer Res. 2023;25:139.
    >> Share

  79. KAZEROUNI AS, Peterson LM, Jenkins I, Novakova-Jiresova A, et al
    Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Breast Cancer Res. 2023;25:138.
    >> Share

  80. WEBSTER JL, Goldstein ND, Rowland JP, Tuite CM, et al
    A catchment and location-allocation analysis of mammography access in Delaware, US: implications for disparities in geographic access to breast cancer screening.
    Breast Cancer Res. 2023;25:137.
    >> Share

  81. HO PJ, Khng AJ, Tan BK, Lim GH, et al
    Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway.
    Breast Cancer Res. 2023;25:136.
    >> Share

  82. CHOI JE, Lee JS, Jin MS, Nikas IP, et al
    The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:134.
    >> Share

  83. MOKBEL K, Alamoodi M
    Exploring the interface zone in breast cancer: implications for surgical strategies and beyond.
    Breast Cancer Res. 2023;25:135.
    >> Share

  84. FLAQUE MCD, Galigniana NM, Beguelin W, Vicario R, et al
    Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
    Breast Cancer Res. 2023;25:133.
    >> Share

  85. YU Y, Ren W, He Z, Chen Y, et al
    Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: a multicenter cohort study.
    Breast Cancer Res. 2023;25:132.
    >> Share

    October 2023
  86. BOUAMAR H, Broome LE, Lathrop KI, Jatoi I, et al
    mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers.
    Breast Cancer Res. 2023;25:131.
    >> Share

  87. BUSUND M, Ursin G, Lund E, Wilsgaard T, et al
    Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer.
    Breast Cancer Res. 2023;25:130.
    >> Share

  88. ZHANG H, Gao M, Zhao W, Yu L, et al
    The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation.
    Breast Cancer Res. 2023;25:129.
    >> Share

  89. YE Z, Nguyen TL, Dite GS, MacInnis RJ, et al
    Causal relationships between breast cancer risk factors based on mammographic features.
    Breast Cancer Res. 2023;25:127.
    >> Share

  90. JUNG J, Kim NH, Kwon M, Park J, et al
    The inhibitory effect of Gremlin-2 on adipogenesis suppresses breast cancer cell growth and metastasis.
    Breast Cancer Res. 2023;25:128.
    >> Share

  91. ZHU S, Zhang M, Liu X, Luo Q, et al
    Single-cell transcriptomics provide insight into metastasis-related subsets of breast cancer.
    Breast Cancer Res. 2023;25:126.
    >> Share

  92. RAMESSUR A, Ambasager B, Valle Aramburu I, Peakman F, et al
    Circulating neutrophils from patients with early breast cancer have distinct subtype-dependent phenotypes.
    Breast Cancer Res. 2023;25:125.
    >> Share

  93. LIU C, Lu C, Yixi L, Hong J, et al
    Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR.
    Breast Cancer Res. 2023;25:124.
    >> Share

  94. SIGURJONSDOTTIR G, De Marchi T, Ehinger A, Hartman J, et al
    Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Breast Cancer Res. 2023;25:123.
    >> Share


  95. Symposium Mammographicum 2023.
    Breast Cancer Res. 2023;25.
    >> Share

  96. GETZ KR, Jeon MS, Luo C, Luo J, et al
    Lipidome of mammographic breast density in premenopausal women.
    Breast Cancer Res. 2023;25:121.
    >> Share

  97. BROEKER CD, Ortiz MMO, Murillo MS, Andrechek ER, et al
    Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.
    Breast Cancer Res. 2023;25:120.
    >> Share

  98. JONAS K, Prinz F, Ferracin M, Krajina K, et al
    MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
    Breast Cancer Res. 2023;25:119.
    >> Share

  99. ZHOU L, Wu J, Ruan M, Xiao Y, et al
    The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.
    Breast Cancer Res. 2023;25:115.
    >> Share

  100. STEENBRUGGEN TG, Wolf DM, Campbell MJ, Sanders J, et al
    B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Breast Cancer Res. 2023;25:117.
    >> Share

  101. OLINDER J, Johnson K, Akesson A, Fornvik D, et al
    Impact of breast density on diagnostic accuracy in digital breast tomosynthesis versus digital mammography: results from a European screening trial.
    Breast Cancer Res. 2023;25:116.
    >> Share

  102. WATSON J, Wang T, Ho KL, Feng Y, et al
    Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
    Breast Cancer Res. 2023;25:114.
    >> Share

  103. QI X, Shi Q, Xuhong J, Zhang Y, et al
    Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
    Breast Cancer Res. 2023;25:113.
    >> Share

  104. DUNLOP HM, Williams LJ, Hall PS, Barber M, et al
    Evaluation of the association of area-level socioeconomic deprivation and breast cancer recurrence by oestrogen receptor subtypes in Scotland.
    Breast Cancer Res. 2023;25:106.
    >> Share

  105. ZOLLNER L, Torres D, Briceno I, Gilbert M, et al
    Native American ancestry and breast cancer risk in Colombian and Mexican women: ruling out potential confounding through ancestry-informative markers.
    Breast Cancer Res. 2023;25:111.
    >> Share

  106. GERRATANA L, Davis AA, Velimirovic M, Clifton K, et al
    Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
    Breast Cancer Res. 2023;25:112.
    >> Share

    September 2023
  107. LUNDGREN C, Tutzauer J, Church SE, Stal O, et al
    Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
    Breast Cancer Res. 2023;25:110.
    >> Share

  108. LUO D, Liang Y, Wang Y, Ye F, et al
    Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD.
    Breast Cancer Res. 2023;25:109.
    >> Share

  109. ZAHL PH
    Re: Non-progressive breast carcinomas detected at mammography screening: a population study-a model test or a novel test of cancer regression?
    Breast Cancer Res. 2023;25:108.
    >> Share

  110. JAN R, Huang M, Lewis-Wambi J
    Retraction Note: Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Breast Cancer Res. 2023;25:107.
    >> Share

  111. SUNDEN M, Norgren S, Lundqvist R, Andersson A, et al
    Receptor conversion and survival in breast cancer liver metastases.
    Breast Cancer Res. 2023;25:105.
    >> Share

  112. BLYTH RRR, Birts CN, Beers SA
    The role of three-dimensional in vitro models in modelling the inflammatory microenvironment associated with obesity in breast cancer.
    Breast Cancer Res. 2023;25:104.
    >> Share

    August 2023
  113. NEVEN P, Fasching PA, Chia S, Jerusalem G, et al
    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
    Breast Cancer Res. 2023;25:103.
    >> Share

  114. HAPACH LA, Wang W, Schwager SC, Pokhriyal D, et al
    Phenotypically sorted highly and weakly migratory triple negative breast cancer cells exhibit migratory and metastatic commensalism.
    Breast Cancer Res. 2023;25:102.
    >> Share

  115. LOFLING LL, Stoer NC, Andreassen BK, Ursin G, et al
    Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
    Breast Cancer Res. 2023;25:101.
    >> Share

  116. YANG W, Xu M, Xu S, Guan Q, et al
    Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors.
    Breast Cancer Res. 2023;25:100.
    >> Share

  117. CASTILLO-CASTREJON M, Sankofi BM, Murguia SJ, Udeme AA, et al
    FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
    Breast Cancer Res. 2023;25:99.
    >> Share

  118. LIU S, Chen W, Hu H, Zhang T, et al
    Correction: Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2023;25:98.
    >> Share

  119. ABUBAKAR M, Klein A, Fan S, Lawrence S, et al
    Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast.
    Breast Cancer Res. 2023;25:97.
    >> Share

  120. ZHOU F, Yang G, Xue L, Liu Y, et al
    SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
    Breast Cancer Res. 2023;25:96.
    >> Share

  121. DEROUEN MC, Yang J, Li Y, Franke AA, et al
    Circulating 27-hydroxycholesterol, lipids, and steroid hormones in breast cancer risk: a nested case-control study of the Multiethnic Cohort Study.
    Breast Cancer Res. 2023;25:95.
    >> Share

  122. MUOIO MG, Pellegrino M, Rapicavoli V, Talia M, et al
    Publisher Correction: RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
    Breast Cancer Res. 2023;25:94.
    >> Share

  123. MIDDHA P, Wang X, Behrens S, Bolla MK, et al
    A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.
    Breast Cancer Res. 2023;25:93.
    >> Share

  124. HABEL LA, Alexeeff SE, Achacoso N, Arasu VA, et al
    Examination of fully automated mammographic density measures using LIBRA and breast cancer risk in a cohort of 21,000 non-Hispanic white women.
    Breast Cancer Res. 2023;25:92.
    >> Share

  125. MARTINEZ-ILLESCAS NG, Leal S, Gonzalez P, Grana-Castro O, et al
    miR-203 drives breast cancer cell differentiation.
    Breast Cancer Res. 2023;25:91.
    >> Share

    July 2023
  126. DAI H, Xu W, Wang L, Li X, et al
    Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development.
    Breast Cancer Res. 2023;25:90.
    >> Share

  127. MOHL A, Behrens S, Flasskamp F, Obi N, et al
    The impact of cardiovascular disease on all-cause and cancer mortality: results from a 16-year follow-up of a German breast cancer case-control study.
    Breast Cancer Res. 2023;25:89.
    >> Share

  128. ZHENG C, Xu X, Wu M, Xue L, et al
    Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance.
    Breast Cancer Res. 2023;25:88.
    >> Share

  129. ADAM R, Dell'Aquila K, Hodges L, Maldjian T, et al
    Deep learning applications to breast cancer detection by magnetic resonance imaging: a literature review.
    Breast Cancer Res. 2023;25:87.
    >> Share

  130. CHUANGCHOT N, Jamjuntra P, Yangngam S, Luangwattananun P, et al
    Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.
    Breast Cancer Res. 2023;25:86.
    >> Share

  131. MUOIO MG, Pellegrino M, Rapicavoli V, Talia M, et al
    RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
    Breast Cancer Res. 2023;25:84.
    >> Share

  132. XIA W, Chen W, Ni C, Meng X, et al
    Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.
    Breast Cancer Res. 2023;25:85.
    >> Share

  133. SMOTHERMAN C, Sprague B, Datta S, Braithwaite D, et al
    Association of air pollution with postmenopausal breast cancer risk in UK Biobank.
    Breast Cancer Res. 2023;25:83.
    >> Share

  134. GERMAN R, Marino N, Hemmerich C, Podicheti R, et al
    Exploring breast tissue microbial composition and the association with breast cancer risk factors.
    Breast Cancer Res. 2023;25:82.
    >> Share

  135. ZHANG J, McAndrew NP, Wang X, Du Y, et al
    Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
    Breast Cancer Res. 2023;25:81.
    >> Share

  136. HEGGLAND T, Vatten LJ, Opdahl S, Weedon-Fekjaer H, et al
    Non-progressive breast carcinomas detected at mammography screening: a population study.
    Breast Cancer Res. 2023;25:80.
    >> Share

    June 2023
  137. PARK AY, Han MR, Seo BK, Ju HY, et al
    MRI-based breast cancer radiogenomics using RNA profiling: association with subtypes in a single-center prospective study.
    Breast Cancer Res. 2023;25:79.
    >> Share

  138. ALVES DA COSTA F, Cardoso Borges F, Ramos A, Mayer A, et al
    Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice.
    Breast Cancer Res. 2023;25:78.
    >> Share

  139. TENG X, Zhang J, Zhang X, Fan X, et al
    Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:77.
    >> Share

  140. KATZENELLENBOGEN BS, Guillen VS, Katzenellenbogen JA
    Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
    Breast Cancer Res. 2023;25:76.
    >> Share

  141. ZHANG Y, Lv L, Zheng R, Xie R, et al
    Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
    Breast Cancer Res. 2023;25:75.
    >> Share


  142. Meeting Abstracts from the British Society of Breast Radiology Annual Scientific Meeting 2022.
    Breast Cancer Res. 2023;25.
    >> Share

  143. KAST K, John EM, Hopper JL, Andrieu N, et al
    Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.
    Breast Cancer Res. 2023;25:72.
    >> Share

  144. LIEFAARD MC, van der Voort A, van Ramshorst MS, Sanders J, et al
    BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
    Breast Cancer Res. 2023;25:71.
    >> Share

  145. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    Correction to: National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:70.
    >> Share

  146. ANDERSEN LVB, Larsen MJ, Davies H, Degasperi A, et al
    Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness.
    Breast Cancer Res. 2023;25:69.
    >> Share

  147. O'LEARY KA, Bates AM, Jin WJ, Burkel BM, et al
    Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    Breast Cancer Res. 2023;25:68.
    >> Share

  148. SCHMID P, Cortes J, Joaquim A, Janez NM, et al
    XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
    Breast Cancer Res. 2023;25:67.
    >> Share

  149. YOUNG KL, Olshan AF, Lunetta K, Graff M, et al
    Influence of alcohol consumption and alcohol metabolism variants on breast cancer risk among Black women: results from the AMBER consortium.
    Breast Cancer Res. 2023;25:66.
    >> Share

  150. ILLIPSE M, Czene K, Hall P, Humphreys K, et al
    Studying the association between longitudinal mammographic density measurements and breast cancer risk: a joint modelling approach.
    Breast Cancer Res. 2023;25:64.
    >> Share

  151. FERRONI G, Sabeti S, Abdus-Shakur T, Scalise L, et al
    Noninvasive prediction of axillary lymph node breast cancer metastasis using morphometric analysis of nodal tumor microvessels in a contrast-free ultrasound approach.
    Breast Cancer Res. 2023;25:65.
    >> Share

  152. YANG C, Liu J, Zhao S, Shang Q, et al
    Infiltrating myeloid cell diversity determines oncological characteristics and clinical outcomes in breast cancer.
    Breast Cancer Res. 2023;25:63.
    >> Share

  153. LIU S, Xie SM, Liu W, Gagea M, et al
    Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
    Breast Cancer Res. 2023;25:62.
    >> Share

    May 2023
  154. XU JB, Cao J, Xia J, Zhu Y, et al
    Breast metastatic tumors in lung can be substituted by lung-derived malignant cells transformed by alternative splicing H19 lncRNA.
    Breast Cancer Res. 2023;25:59.
    >> Share

  155. COELINGH BENNINK HJT, Schultz IJ, Schmidt M, Jordan VC, et al
    Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.
    Breast Cancer Res. 2023;25:60.
    >> Share

  156. LANG M, Liang P, Shen H, Li H, et al
    Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study.
    Breast Cancer Res. 2023;25:61.
    >> Share

  157. MIYASHITA M, Bell JSK, Wenric S, Karaesmen E, et al
    Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
    Breast Cancer Res. 2023;25:58.
    >> Share

  158. TANG X, Thompson KJ, Kalari KR, Sinnwell JP, et al
    Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
    Breast Cancer Res. 2023;25:57.
    >> Share

  159. HOFFMANN E, Gerwing M, Krahling T, Hansen U, et al
    Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
    Breast Cancer Res. 2023;25:56.
    >> Share

  160. QI M, Yi X, Yue B, Huang M, et al
    S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
    Breast Cancer Res. 2023;25:55.
    >> Share

  161. PETERSON JR, Cole JA, Pfeiffer JR, Norris GH, et al
    Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
    Breast Cancer Res. 2023;25:54.
    >> Share

  162. SMID M, Schmidt MK, Prager-van der Smissen WJC, Ruigrok-Ritstier K, et al
    Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
    Breast Cancer Res. 2023;25:53.
    >> Share

  163. VAN DER NOORD VE, van der Stel W, Louwerens G, Verhoeven D, et al
    Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
    Breast Cancer Res. 2023;25:51.
    >> Share

  164. RAMIN C, Veiga LHS, Vo JB, Curtis RE, et al
    Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
    Breast Cancer Res. 2023;25:50.
    >> Share

    April 2023
  165. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:47.
    >> Share

  166. ZHANG J, Qin Z, So TH, Chang TY, et al
    Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an assessor-participant blinded, randomized, sham-controlled trial.
    Breast Cancer Res. 2023;25:49.
    >> Share

  167. RAGU ME, Lim JMC, Ng PS, Yip CH, et al
    TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.
    Breast Cancer Res. 2023;25:48.
    >> Share

  168. LEE S, Toft NJ, Axelsen TV, Espejo MS, et al
    Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer.
    Breast Cancer Res. 2023;25:46.
    >> Share

  169. COHEN SY, Stoll CR, Anandarajah A, Doering M, et al
    Modifiable risk factors in women at high risk of breast cancer: a systematic review.
    Breast Cancer Res. 2023;25:45.
    >> Share

  170. MANI C, Acharya G, Saamarthy K, Ochola D, et al
    Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:44.
    >> Share

  171. LIU H, Yan R, Xiao Z, Huang X, et al
    Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Breast Cancer Res. 2023;25:43.
    >> Share

  172. LE CORNET C, Jung AY, Johnson TS, Behrens S, et al
    Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort.
    Breast Cancer Res. 2023;25:42.
    >> Share

  173. ZHANG X, Gunda A, Kranenbarg EM, Liefers GJ, et al
    Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.
    Breast Cancer Res. 2023;25:40.
    >> Share

  174. MURAKAMI-NISHIMAGI Y, Sugimoto K, Kobayashi M, Tachibana K, et al
    Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor beta.
    Breast Cancer Res. 2023;25:41.
    >> Share

  175. BLISS JM, Tovey H, Evans A, Holcombe C, et al
    Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
    Breast Cancer Res. 2023;25:39.
    >> Share

  176. ZHANG F, Zheng Z, Wang L, Zeng W, et al
    PKC-zeta mediated reduction of the extracellular vesicles-associated TGF-beta1 overcomes radiotherapy resistance in breast cancer.
    Breast Cancer Res. 2023;25:38.
    >> Share

  177. JANEVA S, Krabbe E, Parris TZ, Nasic S, et al
    Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer.
    Breast Cancer Res. 2023;25:36.
    >> Share

  178. DURAN CL, Karagiannis GS, Chen X, Sharma VP, et al
    Cooperative NF-kappaB and Notch1 signaling promotes macrophage-mediated MenaINV expression in breast cancer.
    Breast Cancer Res. 2023;25:37.
    >> Share

    March 2023
  179. MASALA G, Bendinelli B, Caini S, Duroni G, et al
    Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study.
    Breast Cancer Res. 2023;25:35.
    >> Share

  180. HU XE, Yang P, Chen S, Wei G, et al
    Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
    Breast Cancer Res. 2023;25:34.
    >> Share

  181. YAGHJYAN L, Heng YJ, Baker GM, Rosner BA, et al
    Associations of alcohol consumption with breast tissue composition.
    Breast Cancer Res. 2023;25:33.
    >> Share

  182. WIMBERGER P, Blohmer JU, Krabisch P, Link T, et al
    The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
    Breast Cancer Res. 2023;25:32.
    >> Share

  183. ROLLAND AL, Porro B, Kab S, Ribet C, et al
    Impact of breast cancer care pathways and related symptoms on the return-to-work process: results from a population-based French cohort study (CONSTANCES).
    Breast Cancer Res. 2023;25:30.
    >> Share

  184. WANG W, Rana PS, Markovic V, Sossey-Alaoui K, et al
    The WAVE3/beta-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
    Breast Cancer Res. 2023;25:31.
    >> Share

  185. GUNNARSDOTTIR FB, Bendahl PO, Johansson A, Benfeitas R, et al
    Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
    Breast Cancer Res. 2023;25:29.
    >> Share

  186. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:28.
    >> Share

  187. TUNALI G, Yanik H, Ozturk SC, Demirkol-Canli S, et al
    A positive feedback loop driven by fibronectin and IL-1beta sustains the inflammatory microenvironment in breast cancer.
    Breast Cancer Res. 2023;25:27.
    >> Share

  188. PECAR G, Liu S, Hooda J, Atkinson JM, et al
    RET signaling in breast cancer therapeutic resistance and metastasis.
    Breast Cancer Res. 2023;25:26.
    >> Share

  189. CHAUDHARY S, Appadurai MI, Maurya SK, Nallasamy P, et al
    MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
    Breast Cancer Res. 2023;25:25.
    >> Share

  190. HATHAWAY CA, Rice MS, Collins LC, Chen D, et al
    Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
    Breast Cancer Res. 2023;25:24.
    >> Share

    February 2023
  191. CHEN ZH, Tian Y, Zhou GL, Yue HR, et al
    CMTM7 inhibits breast cancer progression by regulating Wnt/beta-catenin signaling.
    Breast Cancer Res. 2023;25:22.
    >> Share

  192. SAEKI S, Kumegawa K, Takahashi Y, Yang L, et al
    Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
    Breast Cancer Res. 2023;25:21.
    >> Share

  193. LEE ES, Kim Y, Shin HC, Hwang KT, et al
    Diagnostic accuracy of a three-protein signature in women with suspicious breast lesions: a multicenter prospective trial.
    Breast Cancer Res. 2023;25:20.
    >> Share

  194. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.
    Breast Cancer Res. 2023;25:18.
    >> Share

  195. OUYANG D, Hong T, Fu M, Li Y, et al
    METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Breast Cancer Res. 2023;25:19.
    >> Share

  196. CHOWDHURY A, Pharoah PD, Rueda OM
    Evaluation and comparison of different breast cancer prognosis scores based on gene expression data.
    Breast Cancer Res. 2023;25:17.
    >> Share

  197. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Correction: Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:16.
    >> Share

  198. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    Correction: A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:15.
    >> Share

    January 2023
  199. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:13.
    >> Share

  200. AYENI OA, Jofe M, Mapanga W, Chen WC, et al
    Correction: Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:14.
    >> Share

  201. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:12.
    >> Share

  202. LIEN HC, Hsu CL, Lu YS, Chen TW, et al
    Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
    Breast Cancer Res. 2023;25:11.
    >> Share

  203. LIU Z, Choksi S, Kwon HJ, Jiao D, et al
    Tumor necroptosis-mediated shedding of cell surface proteins promotes metastasis of breast cancer by suppressing anti-tumor immunity.
    Breast Cancer Res. 2023;25:10.
    >> Share

  204. SCHONBERG MA, Wolfson EA, Eliassen AH, Bertrand KA, et al
    A model for predicting both breast cancer risk and non-breast cancer death among women > 55 years old.
    Breast Cancer Res. 2023;25:8.
    >> Share

  205. WANG Y, Liu F, Sun L, Jia Y, et al
    Association between human blood metabolome and the risk of breast cancer.
    Breast Cancer Res. 2023;25:9.
    >> Share

  206. AYENI OA, Joffe M, Mapanga W, Chen WC, et al
    Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:7.
    >> Share

  207. TODHUNTER ME, Miyano M, Carlson EG, Hinz S, et al
    Sustained postconfluent culture of human mammary epithelial cells enriches for luminal and c-Kit+ subtypes.
    Breast Cancer Res. 2023;25:6.
    >> Share

  208. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:5.
    >> Share

  209. CAO Z, Liu R, Li Y, Luo X, et al
    MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer.
    Breast Cancer Res. 2023;25:3.
    >> Share

  210. KIM CG, Kim MH, Kim JH, Kim SG, et al
    On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
    Breast Cancer Res. 2023;25:4.
    >> Share

  211. DE HAAS SL, Slamon DJ, Martin M, Press MF, et al
    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    Breast Cancer Res. 2023;25:2.
    >> Share

  212. CHEN S, Paul MR, Sterner CJ, Belka GK, et al
    PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
    Breast Cancer Res. 2023;25:1.
    >> Share

    December 2022
  213. ANANDARAJAH A, Chen Y, Colditz GA, Hardi A, et al
    Studies of parenchymal texture added to mammographic breast density and risk of breast cancer: a systematic review of the methods used in the literature.
    Breast Cancer Res. 2022;24:101.
    >> Share

  214. SHAH JS, Milevskiy MJG, Petrova V, Au AYM, et al
    Towards resolution of the intron retention paradox in breast cancer.
    Breast Cancer Res. 2022;24:100.
    >> Share

  215. LUO J, Zou H, Guo Y, Tong T, et al
    SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
    Breast Cancer Res. 2022;24:99.
    >> Share

  216. YADAV N, Sunder R, Desai S, Dharavath B, et al
    Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer.
    Breast Cancer Res. 2022;24:97.
    >> Share

  217. JOE NS, Godet I, Milki N, Ain NUI, et al
    Mebendazole prevents distant organ metastases in part by decreasing ITGbeta4 expression and cancer stemness.
    Breast Cancer Res. 2022;24:98.
    >> Share

  218. LEE ARGOV EJ, Rodriguez CB, Agovino M, Wei Y, et al
    Breast cancer worry, uncertainty, and perceived risk following breast density notification in a longitudinal mammography screening cohort.
    Breast Cancer Res. 2022;24:95.
    >> Share

  219. KIM S, Tran TXM, Song H, Park B, et al
    Microcalcifications, mammographic breast density, and risk of breast cancer: a cohort study.
    Breast Cancer Res. 2022;24:96.
    >> Share

  220. FERNANDEZ G, Prastawa M, Madduri AS, Scott R, et al
    Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years.
    Breast Cancer Res. 2022;24:93.
    >> Share

  221. PAN Y, Yang Y, Huang R, Yang H, et al
    Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors.
    Breast Cancer Res. 2022;24:92.
    >> Share

  222. SIRVEN P, Faucheux L, Grandclaudon M, Michea P, et al
    Definition of a novel breast tumor-specific classifier based on secretome analysis.
    Breast Cancer Res. 2022;24:94.
    >> Share

  223. DORGAN JF, Baer HJ, Bertrand KA, LeBlanc ES, et al
    Childhood adiposity, serum metabolites and breast density in young women.
    Breast Cancer Res. 2022;24:91.
    >> Share

  224. SGROI DC, Treuner K, Zhang Y, Piper T, et al
    Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Breast Cancer Res. 2022;24:90.
    >> Share

  225. YAGHJYAN L, Eliassen AH, Colditz G, Rosner B, et al
    Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
    Breast Cancer Res. 2022;24:89.
    >> Share

  226. SEMINA SE, Alejo LH, Chopra S, Kansara NS, et al
    Identification of a novel ER-NFkB-driven stem-like cell population associated with relapse of ER+ breast tumors.
    Breast Cancer Res. 2022;24:88.
    >> Share

  227. HASSAINE Y, Jacquet E, Seigneurin A, Delafosse P, et al
    Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?
    Breast Cancer Res. 2022;24:87.
    >> Share

  228. DAVIS LYNN BC, Lord BD, Cora R, Pfeiffer RM, et al
    Associations between quantitative measures of TDLU involution and breast tumor molecular subtypes among breast cancer cases in the Black Women's Health Study: a case-case analysis.
    Breast Cancer Res. 2022;24:86.
    >> Share

    November 2022
  229. GU J, Ternifi R, Sabeti S, Larson NB, et al
    Volumetric imaging and morphometric analysis of breast tumor angiogenesis using a new contrast-free ultrasound technique: a feasibility study.
    Breast Cancer Res. 2022;24:85.
    >> Share

  230. PHILIPPSON C, Larsen S, Simon S, Vandekerkhove C, et al
    Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.
    Breast Cancer Res. 2022;24:83.
    >> Share

  231. BALLINGER TJ, Thompson WR, Guise TA
    The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health.
    Breast Cancer Res. 2022;24:84.
    >> Share

  232. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:82.
    >> Share

  233. WU L, Ye W, Liu Y, Chen D, et al
    An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study.
    Breast Cancer Res. 2022;24:81.
    >> Share

  234. BALLOT E, Galland L, Mananet H, Boidot R, et al
    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Breast Cancer Res. 2022;24:80.
    >> Share

  235. KOLYVAS EA, Caldas C, Kelly K, Ahmad SS, et al
    Androgen receptor function and targeted therapeutics across breast cancer subtypes.
    Breast Cancer Res. 2022;24:79.
    >> Share

  236. ASAD S, Damicis A, Heng YJ, Kananen K, et al
    Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
    Breast Cancer Res. 2022;24:78.
    >> Share

  237. PEDERSEN DC, Jensen BW, Tjonneland A, Andersen ZJ, et al
    Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes.
    Breast Cancer Res. 2022;24:77.
    >> Share

  238. SZABOVA L, Gordon MB, Lu L, Pate N, et al
    Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Breast Cancer Res. 2022;24:75.
    >> Share

  239. CRAGER M, Wijayawardana SR, Gruver AM, Blacklock A, et al
    Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score(R) result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
    Breast Cancer Res. 2022;24:74.
    >> Share

    October 2022
  240. HAN SJ, Sung N, Wang J, O'Malley BW, et al
    Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
    Breast Cancer Res. 2022;24:73.
    >> Share

  241. KARTHIKEYAN S, Casey PJ, Wang M
    RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation.
    Breast Cancer Res. 2022;24:72.
    >> Share

  242. LA VERDE N, Damia G, Garrone O, Santini D, et al
    Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
    Breast Cancer Res. 2022;24:71.
    >> Share

  243. DU T, Pan L, Zheng C, Chen K, et al
    Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
    Breast Cancer Res. 2022;24:70.
    >> Share

  244. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:69.
    >> Share

  245. ZHENG ZY, Elsarraj H, Lei JT, Hong Y, et al
    Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Breast Cancer Res. 2022;24:68.
    >> Share

  246. ONAGI H, Horimoto Y, Sakaguchi A, Ikarashi D, et al
    High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
    Breast Cancer Res. 2022;24:67.
    >> Share

  247. NOUNU A, Kar SP, Relton CL, Richmond RC, et al
    Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
    Breast Cancer Res. 2022;24:66.
    >> Share

  248. LUCHTENBORG AM, Metzger P, Cosenza Contreras M, Oria V, et al
    Kruppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.
    Breast Cancer Res. 2022;24:65.
    >> Share

    September 2022
  249. ZIOLKOWSKI P, Wozniak M, Mansour A, An Y, et al
    Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis.
    Breast Cancer Res. 2022;24:64.
    >> Share

  250. DENG N, Minoche A, Harvey K, Li M, et al
    Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models.
    Breast Cancer Res. 2022;24:63.
    >> Share

  251. LOPEZ-KNOWLES E, Detre S, Hills M, Schuster EF, et al
    Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Breast Cancer Res. 2022;24:61.
    >> Share

  252. LI C, Yoshimura T, Tian M, Wang Y, et al
    Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer.
    Breast Cancer Res. 2022;24:60.
    >> Share

  253. LOUDIG O, Mitchell MI, Ben-Dov IZ, Liu C, et al
    MiRNA expression deregulation correlates with the Oncotype DX((R)) DCIS score.
    Breast Cancer Res. 2022;24:62.
    >> Share

  254. DUGUE PA, Bodelon C, Chung FF, Brewer HR, et al
    Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.
    Breast Cancer Res. 2022;24:59.
    >> Share

  255. KOLBERG-LIEDTKE C, Feuerhake F, Garke M, Christgen M, et al
    Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Breast Cancer Res. 2022;24:58.
    >> Share

    August 2022
  256. LIU C, Hu S, Xu X, Zhang Y, et al
    Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment.
    Breast Cancer Res. 2022;24:57.
    >> Share

  257. CLARKE S, Chin SN, Dodds L, George SHL, et al
    Racial disparities in breast cancer preclinical and clinical models.
    Breast Cancer Res. 2022;24:56.
    >> Share

    July 2022
  258. JONES LI, Marshall A, Elangovan P, Geach R, et al
    Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset.
    Breast Cancer Res. 2022;24:55.
    >> Share

  259. LEE S, Osmanbeyoglu HU
    Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
    Breast Cancer Res. 2022;24:54.
    >> Share

  260. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2022;24:53.
    >> Share

  261. HANNA A, Nixon MJ, Estrada MV, Sanchez V, et al
    Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Breast Cancer Res. 2022;24:51.
    >> Share

  262. SALVATI A, Melone V, Sellitto A, Rizzo F, et al
    Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Breast Cancer Res. 2022;24:52.
    >> Share

  263. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2022;24:50.
    >> Share

  264. WARD SV, Burton A, Tamimi RM, Pereira A, et al
    The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density.
    Breast Cancer Res. 2022;24:49.
    >> Share

  265. MIR S, Golden BDO, Griess BJ, Vengoji R, et al
    Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
    Breast Cancer Res. 2022;24:48.
    >> Share

  266. AL-TWEIGERI T, AlRaouji NN, Tulbah A, Arafah M, et al
    High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients.
    Breast Cancer Res. 2022;24:46.
    >> Share

  267. KEHM RD, Walter EJ, Oskar S, White ML, et al
    Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study.
    Breast Cancer Res. 2022;24:47.
    >> Share

  268. OGONY J, de Bel T, Radisky DC, Kachergus J, et al
    Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.
    Breast Cancer Res. 2022;24:45.
    >> Share

    June 2022
  269. WAGNER KU
    Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.
    Breast Cancer Res. 2022;24:44.
    >> Share

  270. PEDERSEN CA, Cao MD, Fleischer T, Rye MB, et al
    DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Breast Cancer Res. 2022;24:43.
    >> Share

  271. WELLBERG EA, Corleto KA, Checkley LA, Jindal S, et al
    Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
    Breast Cancer Res. 2022;24:42.
    >> Share

  272. RATZ L, Brambillasca C, Bartke L, Huetzen MA, et al
    Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Breast Cancer Res. 2022;24:41.
    >> Share

  273. CARR D, Zein A, Coulombe J, Jiang T, et al
    Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.
    Breast Cancer Res. 2022;24:40.
    >> Share

  274. ONG CHC, Lee DY, Lee B, Li H, et al
    Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Breast Cancer Res. 2022;24:38.
    >> Share

  275. HARRASSER M, Gohil SH, Lau H, Della Peruta M, et al
    Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Breast Cancer Res. 2022;24:39.
    >> Share

  276. SIEGEL SD, Brooks MM, Lynch SM, Sims-Mourtada J, et al
    Racial disparities in triple negative breast cancer: toward a causal architecture approach.
    Breast Cancer Res. 2022;24:37.
    >> Share

    May 2022
  277. KOEVOETS EW, Schagen SB, de Ruiter MB, Geerlings MI, et al
    Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
    Breast Cancer Res. 2022;24:36.
    >> Share

  278. RAGHAVAKAIMAL A, Cristofanilli M, Tang CM, Alpaugh RK, et al
    CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.
    Breast Cancer Res. 2022;24:35.
    >> Share

  279. RALLI GP, Carter RD, McGowan DR, Cheng WC, et al
    Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.
    Breast Cancer Res. 2022;24:34.
    >> Share

  280. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
    Breast Cancer Res. 2022;24:29.
    >> Share

  281. ROUSSEAU B, Murugan S, Palagani A, Sarkar DK, et al
    Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.
    Breast Cancer Res. 2022;24:33.
    >> Share

  282. ZHENG J, Zhang B
    Biological interpretation of prognostic radiomic score by correlating with tumor heterogeneity and microenvironment.
    Breast Cancer Res. 2022;24:32.
    >> Share

  283. HO WJ, Law AMK, Masle-Farquhar E, Castillo LE, et al
    Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.
    Breast Cancer Res. 2022;24:31.
    >> Share

    April 2022
  284. GRINMAN DY, Boras-Granic K, Takyar FM, Dann P, et al
    PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.
    Breast Cancer Res. 2022;24:30.
    >> Share

  285. MINTZ R, Wang M, Xu S, Colditz GA, et al
    Hormone and receptor activator of NF-kappaB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.
    Breast Cancer Res. 2022;24:28.
    >> Share

  286. CHEN H, Fan S, Stone J, Thompson DJ, et al
    Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.
    Breast Cancer Res. 2022;24:27.
    >> Share

  287. LIU Z, Liu J, Ebrahimi B, Pratap UP, et al
    SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Breast Cancer Res. 2022;24:26.
    >> Share

  288. FOO SL, Sachaphibulkij K, Lee CLY, Yap GLR, et al
    Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1/formyl peptide receptor signaling.
    Breast Cancer Res. 2022;24:25.
    >> Share

  289. RENAULT AL, Dowty JG, Steen JA, Li S, et al
    Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
    Breast Cancer Res. 2022;24:24.
    >> Share

  290. HEYNEN GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, et al
    Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
    Breast Cancer Res. 2022;24:23.
    >> Share

    March 2022
  291. WON HS, Ahn J, Kim Y, Kim JS, et al
    Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res. 2022;24:22.
    >> Share

  292. TU CF, Li FA, Li LH, Yang RB, et al
    Quantitative glycoproteomics analysis identifies novel FUT8 targets and signaling networks critical for breast cancer cell invasiveness.
    Breast Cancer Res. 2022;24:21.
    >> Share

  293. WANG X, Xie T, Luo J, Zhou Z, et al
    Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment.
    Breast Cancer Res. 2022;24:20.
    >> Share

  294. SEMINA SE, Pal P, Kansara NS, Huggins RJ, et al
    Selective pressure of endocrine therapy activates the integrated stress response through NFkappaB signaling in a subpopulation of ER positive breast cancer cells.
    Breast Cancer Res. 2022;24:19.
    >> Share

  295. LIU M, Smith R, Liby T, Chiotti K, et al
    INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
    Breast Cancer Res. 2022;24:18.
    >> Share

  296. WATT AC, Goel S
    Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer.
    Breast Cancer Res. 2022;24:17.
    >> Share

  297. GU J, Ternifi R, Larson NB, Carter JM, et al
    Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization.
    Breast Cancer Res. 2022;24:16.
    >> Share

    February 2022
  298. SYRIOPOULOU E, Gasparini A, Humphreys K, Andersson TM, et al
    Assessing lead time bias due to mammography screening on estimates of loss in life expectancy.
    Breast Cancer Res. 2022;24:15.
    >> Share

  299. GASTOUNIOTI A, Desai S, Ahluwalia VS, Conant EF, et al
    Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review.
    Breast Cancer Res. 2022;24:14.
    >> Share

  300. THOMPSON KN, Ju JA, Ory EC, Pratt SJP, et al
    Microtubule disruption reduces metastasis more effectively than primary tumor growth.
    Breast Cancer Res. 2022;24:13.
    >> Share

  301. SUN L, Ding H, Jia Y, Shi M, et al
    Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Breast Cancer Res. 2022;24:12.
    >> Share

  302. WEI G, Teng M, Rosa M, Wang X, et al
    Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Breast Cancer Res. 2022;24:11.
    >> Share

    January 2022
  303. REN Q, Khoo WH, Corr AP, Phan TG, et al
    Gene expression predicts dormant metastatic breast cancer cell phenotype.
    Breast Cancer Res. 2022;24:10.
    >> Share

  304. GECZIK AM, Falk RT, Xu X, Ansong D, et al
    Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study.
    Breast Cancer Res. 2022;24:9.
    >> Share

  305. TANG YH, Rockstroh A, Sokolowski KA, Lynam LR, et al
    Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
    Breast Cancer Res. 2022;24:8.
    >> Share

  306. YIN L, Li Q, Mrdenovic S, Chu GC, et al
    KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.
    Breast Cancer Res. 2022;24:7.
    >> Share

  307. DESHPANDE RP, Sharma S, Liu Y, Pandey PR, et al
    LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
    Breast Cancer Res. 2022;24:6.
    >> Share

  308. PIRIKAHU S, Lund H, Cadby G, Wylie E, et al
    The impact of breast density notification on rescreening rates within a population-based mammographic screening program.
    Breast Cancer Res. 2022;24:5.
    >> Share

  309. HJERKIND KV, Johansson ALV, Trewin CB, Russnes HG, et al
    Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway.
    Breast Cancer Res. 2022;24:4.
    >> Share

  310. YOON L, Corvalan C, Pereira A, Shepherd J, et al
    Sugar-sweetened beverage consumption and breast composition in a longitudinal study of Chilean girls.
    Breast Cancer Res. 2022;24:3.
    >> Share

  311. MENG L, Chang S, Sang Y, Ding P, et al
    Circular RNA circCCDC85A inhibits breast cancer progression via acting as a miR-550a-5p sponge to enhance MOB1A expression.
    Breast Cancer Res. 2022;24:1.
    >> Share

  312. AHEARN TU, Zhang H, Michailidou K, Milne RL, et al
    Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
    Breast Cancer Res. 2022;24:2.
    >> Share

    December 2021
  313. NIWINSKA A, Olszewski WP
    The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
    Breast Cancer Res. 2021;23:118.
    >> Share

  314. SANDSVEDEN M, Borgquist S, Rosendahl AH, Manjer J, et al
    Low thyroid hormone receptor alpha-2 (THRalpha-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.
    Breast Cancer Res. 2021;23:117.
    >> Share

  315. CHEUNG AM, Wang D, Liu K, Hope T, et al
    Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.
    Breast Cancer Res. 2021;23:114.
    >> Share

  316. ZHANG M, Meng M, Liu Y, Qi J, et al
    Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
    Breast Cancer Res. 2021;23:116.
    >> Share

  317. LIU S, Chen W, Hu H, Zhang T, et al
    Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2021;23:115.
    >> Share

  318. YAGHOOBI V, Moutafi M, Aung TN, Pelekanou V, et al
    Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
    Breast Cancer Res. 2021;23:113.
    >> Share

  319. GAMPENRIEDER SP, Rinnerthaler G, Tinchon C, Petzer A, et al
    Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
    Breast Cancer Res. 2021;23:112.
    >> Share

  320. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
    Early-life exposures and age at thelarche in the Sister Study cohort.
    Breast Cancer Res. 2021;23:111.
    >> Share

    November 2021
  321. VIROSTKO J, Sorace AG, Slavkova KP, Kazerouni AS, et al
    Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting.
    Breast Cancer Res. 2021;23:110.
    >> Share

  322. BOUCHERON P, Anele A, Zietsman A, Galukande M, et al
    Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study.
    Breast Cancer Res. 2021;23:109.
    >> Share

  323. LABRECHE C, Cook DP, Abou-Hamad J, Pascoal J, et al
    Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFbeta/PI3K/AKT pathways.
    Breast Cancer Res. 2021;23:107.
    >> Share

  324. BARBER LE, Zirpoli GR, Cozier YC, Rosenberg L, et al
    Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women.
    Breast Cancer Res. 2021;23:108.
    >> Share

  325. LIU FC, Veierod MB, Kjaerheim K, Robsahm TE, et al
    Excess risk of male breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a possible link to extreme night shift work?
    Breast Cancer Res. 2021;23:106.
    >> Share

  326. BODELON C, Mullooly M, Pfeiffer RM, Fan S, et al
    Mammary collagen architecture and its association with mammographic density and lesion severity among women undergoing image-guided breast biopsy.
    Breast Cancer Res. 2021;23:105.
    >> Share

  327. JESSER EA, Brady NJ, Huggins DN, Witschen PM, et al
    STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment.
    Breast Cancer Res. 2021;23:104.
    >> Share

  328. HANAMURA T, Christenson JL, O'Neill KI, Rosas E, et al
    Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
    Breast Cancer Res. 2021;23:102.
    >> Share

  329. COLLIN LJ, Maliniak ML, Cronin-Fenton DP, Ahern TP, et al
    Hypoxia-inducible factor-1alpha expression and breast cancer recurrence in a Danish population-based case control study.
    Breast Cancer Res. 2021;23:103.
    >> Share

    October 2021
  330. ROPRI AS, DeVaux RS, Eng J, Chittur SV, et al
    Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Breast Cancer Res. 2021;23:101.
    >> Share

  331. SCHERER SD, Riggio AI, Haroun F, DeRose YS, et al
    An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
    Breast Cancer Res. 2021;23:100.
    >> Share

  332. SAKAGUCHI A, Horimoto Y, Onagi H, Ikarashi D, et al
    Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res. 2021;23:99.
    >> Share

  333. FUH KF, Shepherd RD, Withell JS, Kooistra BK, et al
    Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.
    Breast Cancer Res. 2021;23:97.
    >> Share

  334. CHEN X, Chen DG, Zhao Z, Balko JM, et al
    Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.
    Breast Cancer Res. 2021;23:96.
    >> Share

  335. HAZLETT J, Niemi V, Aiderus A, Powell K, et al
    Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2021;23:95.
    >> Share

    September 2021
  336. LIOU L, Kaptoge S, Dennis J, Shah M, et al
    Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
    Breast Cancer Res. 2021;23:94.
    >> Share

  337. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
    Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
    Breast Cancer Res. 2021;23:91.
    >> Share

  338. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
    Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
    Breast Cancer Res. 2021;23:93.
    >> Share

  339. ZARE A, Postovit LM, Githaka JM
    Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Breast Cancer Res. 2021;23:92.
    >> Share

  340. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
    A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Breast Cancer Res. 2021;23:90.
    >> Share

  341. YANG L, Wang B, Jiao X, Zhou C, et al
    TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
    Breast Cancer Res. 2021;23:89.
    >> Share

    July 2021
  342. HIS M, Lajous M, Gomez-Flores-Ramos L, Monge A, et al
    Biomarkers of mammographic density in premenopausal women.
    Breast Cancer Res. 2021;23:75.
    >> Share

  343. LU P, Foley J, Zhu C, McNamara K, et al
    Transcriptome and genome evolution during HER2-amplified breast neoplasia.
    Breast Cancer Res. 2021;23:73.
    >> Share

  344. GARZIA NA, Cushing-Haugen K, Kensler TW, Tamimi RM, et al
    Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density.
    Breast Cancer Res. 2021;23:71.
    >> Share

    June 2021
  345. RUTH JR, Pant DK, Pan TC, Seidel HE, et al
    Cellular dormancy in minimal residual disease following targeted therapy.
    Breast Cancer Res. 2021;23:63.
    >> Share

    May 2021
  346. SARRADIN V, Lusque A, Filleron T, Dalenc F, et al
    Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Breast Cancer Res. 2021;23:61.
    >> Share

  347. DE BOER LL, Kho E, Van de Vijver KK, Vranken Peeters MTFD, et al
    Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance.
    Breast Cancer Res. 2021;23:59.
    >> Share

  348. CONG L, Maishi N, Annan DA, Young MF, et al
    Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
    Breast Cancer Res. 2021;23:51.
    >> Share

    April 2021
  349. REIMERS LL, Goldberg M, Tehranifar P, Michels KB, et al
    Benign breast disease and changes in mammographic breast density.
    Breast Cancer Res. 2021;23:49.
    >> Share

  350. YANG HY, Tu CW, Chen CC, Lee CY, et al
    Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience.
    Breast Cancer Res. 2021;23:43.
    >> Share

    February 2021
  351. SZUCS Z, Joseph J, Larkin TJ, Xie B, et al
    Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
    Breast Cancer Res. 2021;23:25.
    >> Share

  352. TIAN J, Wang V, Wang N, Khadang B, et al
    Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
    Breast Cancer Res. 2021;23:23.
    >> Share

    January 2021
  353. ALTOE ML, Kalinsky K, Marone A, Kim HK, et al
    Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
    Breast Cancer Res. 2021;23:16.
    >> Share

  354. BAI F, Liu S, Liu X, Hollern DP, et al
    PDGFRbeta is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Breast Cancer Res. 2021;23:10.
    >> Share

  355. RIEDLINGER GM, Joshi S, Hirshfield KM, Barnard N, et al
    Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
    Breast Cancer Res. 2021;23:7.
    >> Share

  356. MCCART REED AE, Kalinowski L, Simpson PT, Lakhani SR, et al
    Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
    Breast Cancer Res. 2021;23:6.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016